Urinary leukotriene E4 is associated with renal function but not with endothelial function in type 2 diabetes

Disease Markers

Volumn 35, Issue 5, 2013, Pages 475-480

  Rafnsson, Arnar ^a   Bäck, Magnus ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Centre for Molecular Medicine   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; C REACTIVE PROTEIN; CHOLESTEROL; CREATININE; GLYCERYL TRINITRATE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEUKOTRIENE E4; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

ADULT; AGED; ARTERY BLOOD FLOW; ARTICLE; BLOOD PRESSURE CUFF; BLOOD VESSEL FUNCTION; BLOOD VESSEL PARAMETERS; BODY MASS; BRACHIAL ARTERY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COLORIMETRY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE DURATION; DOUBLE BLIND PROCEDURE; ELISA KIT; ENDOTHELIAL DYSFUNCTION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPEREMIA; INDEX FINGER; KIDNEY FUNCTION; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHOTOMETER; PNEUMATIC PLETHYSMOGRAPH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REACTIVE HYPEREMIA INDEX; SYSTOLIC BLOOD PRESSURE; TONOMETRY; TRIACYLGLYCEROL BLOOD LEVEL; TURBIDIMETRY; URINALYSIS; URINE LEVEL; VASCULAR ENDOTHELIUM; VASODILATATION; WAIST CIRCUMFERENCE;

AGED; BIOLOGICAL MARKERS; BRACHIAL ARTERY; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; ENDOTHELIUM, VASCULAR; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; LEUKOTRIENE E4; MALE; MIDDLE AGED; VASODILATION;

EID: 84890337921     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2013/370461     Document Type: Article

References (42)

1. M. Bäck, S.-E. Dahlén, J. M. Drazen et al., "International union of basic and clinical pharmacology. LXXXIV: leukotriene receptor nomenclature, distribution, and pathophysiological functions," Pharmacological Reviews, vol. 63, no. 3, pp. 539-584, 2011.
2. F. Stanke-Labesque, M. Bäck, B. Lefebvre et al., "Increased urinary leukotriene E4 excretion in obstructive sleep apnea: effects of obesity and hypoxia," Journal of Allergy and Clinical Immunology, vol. 124, no. 2, pp. 364.e2-370.e2, 2009.
3. M. Carry, V. Korley, J. T. Willerson, L. Weigelt, A. W. Ford-Hutchinson, and P. Tagari, "Increased urinary leukotriene excretion in patients with cardiac ischemia: in vivo evidence for 5-lipoxygenase activation," Circulation, vol. 85, no. 1, pp. 230-236, 1992.
4. G. Hardy, R. Boizel, J. Bessard et al., "Urinary leukotriene E4 excretion is increased in type 1 diabetic patients: a quantification by liquid chromatography-tandem mass spectrometry," Prostaglandins and Other Lipid Mediators, vol. 78, no. 1-4, pp. 291-299, 2005.
5. M. Bäck, A. Sultan, O. Ovchinnikova, and G. K. Hansson, "5-Lipoxygenase-activating protein: a potential link between innate and adaptive immunity in atherosclerosis and adipose tissue inflammation," Circulation Research, vol. 100, no. 7, pp. 946-949, 2007.
6. M. Spite, J. Hellmann, Y. Tang et al., "Deficiency of the leukotriene B4 receptor, BLT-1, protects against systemic insulin resistance in diet-induced obesity," Journal of Immunology, vol. 187, no. 4, pp. 1942-1949, 2011.
7. I. Mothe-Satney, C. Filloux, H. Amghar et al., "Adipocytes secrete leukotrienes: contribution to obesity-associated inflammation and insulin resistance in mice," Diabetes, vol. 61, pp. 2311-2319, 2012.
8. F. Paneni, J. A. Beckman, M. A. Creager, and F. Cosentino, "Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I," European Heart Journal, vol. 34, no. 31, pp. 2436-2443, 2013.
9. A. E. Caballero, S. Arora, R. Saouaf et al., "Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes," Diabetes, vol. 48, no. 9, pp. 1856-1862, 1999.
10. M. Bäck, "Inhibitors of the 5-lipoxygenase pathway in atherosclerosis," Current Pharmaceutical Design, vol. 15, no. 27, pp. 3116-3132, 2009.
11. G. Riccioni and M. Bäck, "Leukotrienes as modifiers of preclinical atherosclerosis?" The ScientificWorld Journal, vol. 2012, Article ID 490968, 2012.
12. M. Bäck, "Leukotriene receptors: crucial components in vascular inflammation," The ScientificWorld Journal, vol. 7, pp. 1422-1439, 2007.
13. J. L. Ortiz, I. Gorenne, J. Cortijo et al., "Leukotriene receptors on human pulmonary vascular endothelium," British Journal of Pharmacology, vol. 115, no. 8, pp. 1382-1386, 1995.
14. M. Bäck, X. Norel, L. Walch et al., "Prostacyclin modulation of contractions of the human pulmonary artery by cysteinylleukotrienes," European Journal of Pharmacology, vol. 401, no. 3, pp. 389-395, 2000.
15. C. Labat, M. Temmar, E. Nagy et al., "Inflammatory mediators in saliva associated with arterial stiffness and subclinical atherosclerosis," Journal of Hypertension, 2013.
16. C. M.McEniery, S.Wallace, I. S.MacKenzie et al., "Endothelial function is associated with pulse pressure, pulse wave velocity, and augmentation index in healthy humans," Hypertension, vol. 48, no. 4, pp. 602-608, 2006.
17. A. Rafnsson, F. Böhm, M. Settergren, A. Gonon, K. Brismar, and J. Pernow, "The endothelin receptor antagonist bosentan improves peripheral endothelial function in patients with type 2 diabetes mellitus and microalbuminuria: a randomised trial," Diabetologia, vol. 55, no. 3, pp. 600-607, 2012.
18. A. Nohria, M. Gerhard-Herman, M. A. Creager, S. Hurley, D. Mitra, and P. Ganz, "Role of nitric oxide in the regulation of digital pulse volume amplitude in humans," Journal of Applied Physiology, vol. 101, no. 2, pp. 545-548, 2006.
19. P. O. Bonetti, G. W. Barsness, P. C. Keelan et al., "Enhanced external counterpulsation improves endothelial function in patients with symptomatic coronary artery disease," Journal of the American College of Cardiology, vol. 41, no. 10, pp. 1761-1768, 2003.
20. N. M. Hamburg and E. J. Benjamin, "Assessment of endothelial function using digital pulse amplitude tonometry," Trends in Cardiovascular Medicine, vol. 19, no. 1, pp. 6-11, 2009.
21. M. Settergren, F. Böhm, L. Rydén, and J. Pernow, "Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease," European Heart Journal, vol. 29, no. 14, pp. 1753-1760, 2008.
22. L. Ghiadoni, A. Cupisti, Y. Huang et al., "Endothelial dysfunction and oxidative stress in chronic renal failure," Journal of Nephrology, vol. 17, no. 4, pp. 512-519, 2004.
23. F. U. S. Mattace-Raso, T. J. M. van der Cammen, I. M. van der Meer et al., "C-reactive protein and arterial stiffness in older adults: the Rotterdam Study," Atherosclerosis, vol. 176, no. 1, pp. 111-116, 2004.
24. S. Makita, M. Nakamura, and K. Hiramori, "The association of C-reactive protein levels with carotid intima-media complex thickness and plaque formation in the general population," Stroke, vol. 36, no. 10, pp. 2138-2142, 2005.
25. H. Hashimoto, K. Kitagawa, H. Hougaku et al., "C-reactive protein is an independent predictor of the rate of increase in early carotid atherosclerosis," Circulation, vol. 104, no. 1, pp. 63-67, 2001.
26. P. M. Ridker, J. E. Buring, N. R. Cook, and N. Rifai, "Creactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women," Circulation, vol. 107, no. 3, pp. 391-397, 2003.
27. O. Schnell, I. Amann-Zalan, Z. Jelsovsky et al., "Changes in A1C levels are significantly associated with changes in levels of the cardiovascular risk biomarker hs-CRP: results from the SteP study," Diabetes Care, vol. 36, no. 7, pp. 2084-2089, 2013.
28. K. S. Heffernan, R. H. Karas, E. A. Patvardhan, H. Jafri, and J. T. Kuvin, "Peripheral arterial tonometry for risk stratification in men with coronary artery disease," Clinical Cardiology, vol. 33, no. 2, pp. 94-98, 2010.
29. C. Vitale, E. Cerquetani, M.Wajngarten et al., "In patients with coronary artery disease endothelial function is associated with plasma levels of C-reactive protein and is improved by optimal medical therapy," ItalianHeart Journal, vol. 4, no.9,pp. 627-632, 2003.
30. S. Verma, C.-H. Wang, E. Lonn et al., "Cross-sectional evaluation of brachial artery flow-mediated vasodilation and Creactive protein in healthy individuals," EuropeanHeart Journal, vol. 25, no. 19, pp. 1754-1760, 2004.
31. P. Giouleka, G. Papatheodorou, P. Lyberopoulos et al., "Body mass index is associated with leukotriene inflammation in asthmatics," European Journal of Clinical Investigation, vol. 41, no. 1, pp. 30-38, 2011.
32. R. Boizel, G. Bruttmann, P. Y. Benhamou, S. Halimi, and F. Stanke-Labesque, "Regulation of oxidative stress and inflammation by glycaemic control: evidence for reversible activation of the 5-lipoxygenase pathway in type 1, but not in type 2 diabetes," Diabetologia, vol. 53, no. 9, pp. 2068-2070, 2010.
33. N. Higashi, M. Taniguchi, H. Mita et al., "Clinical features of asthmatic patients with increased urinary leukotriene E4 excretion (hyperleukotrienuria): involvement of chronic hyperplastic rhinosinusitis with nasal polyposis," The Journal of Allergy and Clinical Immunology, vol. 113, no. 2, pp. 277-283, 2004.
34. S. W. Reinhold, T. Scherl, B. Stolcker et al., "Lipoxygenase products in the urine correlate with renal function and body temperature but not with acute transplant rejection," Lipids, vol. 48, no. 2, pp. 167-175, 2013.
35. R. Petric and A. W. Ford-Hutchinson, "Elevated cysteinyl leukotriene excretion in experimental glomerulonephritis," Kidney International, vol. 46, no. 5, pp. 1322-1329, 1994.
36. J. M. Valdivielso, A. Montero, K. F. Badr, and K. A. Munger, "Inhibition of 5-lipoxygenase activating protein decreases proteinuria in diabetic rats," Journal of nephrology, vol. 16, no. 1, pp. 85-94, 2003.
37. E. Noiri, T. Yokomizo, A. Nakao et al., "An in vivo approach showing the chemotactic activity of leukotriene B4 in acute renal ischemic-reperfusion injury," Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 2, pp. 823-828, 2000.
38. D.W. Butterly, R. F. Spurney, P. Ruiz, R. Griffiths, C. Albrightson, and T.M. Coffman, "A role for leukotrienes in cyclosporine nephrotoxicity, " Kidney International, vol. 57, no. 6, pp. 2586-2593, 2000.
39. K. P. Moore, G. W. Taylor, N. H. Maltby et al., "Increased production of cysteinyl leukotrienes in hepatorenal syndrome," Journal of Hepatology, vol. 11, no. 2, pp. 263-271, 1990.
40. D. A. Brezinski, R. W. Nesto, and C. N. Serhan, "Angioplasty triggers intracoronary leukotrienes and lipoxin A4: impact of aspirin therapy," Circulation, vol. 86, no. 1, pp. 56-63, 1992.
41. X. Houard, V. Ollivier, L. Louedec, J.-B. Michel, and M. Bäck, "Differential inflammatory activity across human abdominal aortic aneurysms reveals neutrophil-derived leukotriene B4 as a major chemotactic factor released from the intraluminal thrombus," FASEB Journal, vol. 23, no. 5, pp. 1376-1383, 2009.
42. F. Stanke-Labesque, J. L. Pepin, T. de Jouvencel et al., "Leukotriene B4 pathway activation and atherosclerosis in obstructive sleep apnea," Journal of Lipid Research, vol. 53, pp. 1944-1951, 2012.